Key statistics
SmartText not available for this item.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | -- |
|---|---|
| High | 172.00 |
| Low | 172.00 |
| Bid | -- |
| Offer | -- |
| Previous close | 172.00 |
| Average volume | -- |
|---|---|
| Shares outstanding | 139.13m |
| Free float | 124.67m |
| P/E (TTM) | -- |
| Market cap | 962.75m USD |
| EPS (TTM) | -3.62 USD |
Data delayed at least 20 minutes, as of Sep 13 2023 12:30 BST.
More ▼
Press releases
- Vir Biotechnology Provides Updates on Chronic Hepatitis Delta and Oncology Programs and Upcoming 2026 Clinical Milestones
- Vir Biotechnology to Present at the 44th Annual J.P. Morgan Healthcare Conference
- Vir Biotechnology Grants Norgine Exclusive Commercial License to Chronic Hepatitis Delta Treatment Candidate in Europe, Australia & New Zealand, Including Global Cost Sharing Agreement for Ongoing ECLIPSE Clinical Development Program
- Vir Biotechnology to Participate in the 8th Annual Evercore Healthcare Conference
- Vir Biotechnology Announces AASLD The Liver Meeting® Presentation & New England Journal of Medicine Publication of Phase 2 Data Demonstrating Tobevibart & Elebsiran Combination Deliver High Rates of Undetectable HDV RNA with Favorable Safety Profile
More ▼
